Highlights ALX Oncology Holdings Inc.

Equities

ALXO

US00166B1052

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-31 pm EDT			5-day change	1st Jan Change
10.63 ^USD	-0.19%		-19.29%	-28.61%

May. 09	ALX Oncology Holdings Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
May. 08	Alx Oncology Holdings Insider Sold Shares Worth $318,334, According to a Recent SEC Filing	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

ALX Oncology Holdings Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 09	CI
ALX Oncology Holdings Inc. Announces Initiation of Phase 2 Investigator-Sponsored Trial of Neoadjuvant Radiation and Evorpacept in Combination with Pembrolizumab in Patients with Untreated HPV-Mediated Oropharyngeal Cancer	Apr. 30	CI
ALX Oncology Reports Positive Data From Ongoing Phase 1/2 Trial of Evorpacept	Apr. 10	MT
ALX Oncology Holdings Inc. Reports Encouraging Clinical Data of Evorpacept in Combination with Standard-of-Care in an Ongoing Phase 1/2 Clinical Trial in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (?R/R B-NHL?)	Apr. 09	CI
North American Morning Briefing : Stock Futures -2-	Mar. 11	DJ
ALX Oncology Holdings Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 07	CI
North American Morning Briefing : Investors Await -2-	Dec. 11	DJ
ALX Oncology Reports Q3 Results With 'Sufficient' Funds to Finance Operations Into Early 2026	Nov. 13	MT
ALX Oncology Q3 Net Loss Widens; Shares Ease After Hours	Nov. 13	MT
ALX Oncology Holdings Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
ALX Oncology Holdings Inc. Reports Positive Interim Phase 2 ASPEN-06 Clinical Trial Results of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer	23-10-03	CI
ALX Oncology Holdings Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI
ALX Oncology's Gastric Cancer Drug Receives European Commission's Orphan Drug Designation	23-06-26	MT
ALX Oncology Holdings Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-11	CI
Alx Oncology Announces Clinical Trial Collaboration with Sanofi to Evaluate Evorpacept in Combination with Sarclisa (Isatuximab-Irfc) in Patients with Multiple Myeloma	23-04-25	CI
ALX Oncology Holdings Inc. and Quantum Leap Healthcare Collaborative Announces First Patient Dosed in the I-SPY-P1 TRIAL in Breast Cancer	23-03-13	CI
ALX Oncology Holdings Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-09	CI
ALX Oncology Holdings Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23-03-09	CI
ALX Oncology Announces First Patient Dosed in ASPEN-07, a Phase 1 Study of Evorpacept for the Treatment of Patients with Urothelial Cancer	23-02-16	CI
Alx Oncology Announces Initial Data from Aspen-05 Study of Evorpacept in Combination with Azacitidine and Venetoclax, Demonstrating Tolerability and Preliminary Activity in Patients with Acute Myeloid Leukemia	22-12-12	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights ALX Oncology Holdings Inc.

Equities

ALXO

US00166B1052

Highlights

Filters